AU - Breast cancer vaccine trial set for 2015

Options

Comments

  • farmerlucy
    farmerlucy Member Posts: 3,985
    edited September 2014

    Very exciting but I wonder what he means by this - 

    He said women with early stage breast cancer are currently treated with hormone therapy after surgery.

    "The problem is that it only works for 10-12 months," Dr Leong said.

  • MusicLover
    MusicLover Member Posts: 4,225
    edited September 2014

    I am not early stage unfortunately but it is good news.  I was wondering the same thing Lucy, so then why do they have women take it for 5 or even 10 years?  I don't think that his statement is well founded.

  • farmerlucy
    farmerlucy Member Posts: 3,985
    edited September 2014

    ML - I'm wondering if he meant 10 -12 years - but that doesn't fit in the context of his statement either.

  • april485
    april485 Member Posts: 3,257
    edited September 2014

    Maybe he meant 10-12 months after stopping the AI? Hmmm, who knows what he meant by that. It is exciting research though!

  • Racy
    Racy Member Posts: 2,651
    edited September 2014

    Maybe he meant 'for some women' as the article refers to relapse rate within three years.

    I pray that the vaccine works!


  • farmerlucy
    farmerlucy Member Posts: 3,985
    edited September 2014

    I emailed the company for a clarification. Maybe he is saying that for those who recur within 3 years (the line above the quote posted above) HT only works for 10 - 12 months. I'll post any response I get. 

  • farmerlucy
    farmerlucy Member Posts: 3,985
    edited September 2014

    They sent me a press release that further explains the results. Here is the pertinent information.

    ASN-004 (Breast Cancer)

    The second treatment, ASN-004, is being developed as a therapeutic vaccine for treating breast

    cancer. ASN-004 is an improved version of a vaccine (OM-MUC-1) and platform originally developed

    at Melbourne’s Burnet Institute (formerly the Austin research Institute), ASN-004 can target breast

    cancer which arises in an estimated 514,750 individuals in the US, Western Europe and Japan.

    The predecessor to ASN-004 was studied in a series of investigator-led clinical trials by the Burnet

    Institute in Australia and Overseas over a 15-year period.

    “Of particular note were the striking results from the use of OM-MUC-1 in a double blind

    randomized placebo controlled study performed in early breast cancer patients,” commented Dr

    Leong.

    Early stage breast cancer is currently treated by removing or treating the primary cancer, but in 25

    to 35 per cent of cases, the cancer will return up to three years later in the form of metastatic breast

    cancer, which is currently incurable. In the OM-MUC-1 breast cancer trial, at the 10-year mark, eight

    out of 15 patients (53%) in the placebo group had their cancer return, compared to only one out of

    16 (6%) in the vaccine treated group.

    “Ascend plans to demonstrate improved potency with ASN-004 and to evaluate its potential use in

    both early and advanced breast cancer,” Dr Leong said

  • geewhiz
    geewhiz Member Posts: 1,439
    edited September 2014

    Somebody help me with this study math...is this saying that without the vaccine my odds are 50% of it returning by year 10? That sucks!

Categories